Loading the section…

SRPT: financial statements from SEC — TradeAlmanac

SRPT

Sarepta Therapeutics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Revenue	731M	443M	399M	611M	745M	658M	467M	363M
Selling, general and administrative	109M	—	92M	138M	134M	—	128M	139M
Operating expenses	372M	—	503M	496M	1.05B	—	445M	364M
Operating income	358M	—	−103M	116M	−300M	—	22M	−701,000
Pre-tax income	343M	—	−194M	154M	−384M	—	34M	14M
Income tax	12M	—	−14M	−43M	64M	—	395,000	7M
Net income	331M	−412M	−51M	197M	−448M	159M	34M	6M
Earnings per share	3.15	−3.93	−0.50	2.01	−4.60	1.65	0.35	0.07
Earnings per share, diluted	2.88	−3.93	−0.50	1.89	−4.60	1.50	0.34	0.07
Weighted average shares	105M	—	100M	98M	97M	—	95M	95M
Weighted average shares, diluted	122M	—	100M	107M	97M	—	100M	99M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	464M	801M	613M	511M	241M	1.10B	198M	384M
Short-term investments	189M	138M	238M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−203M	−583M
Depreciation and amortisation	11M	10M
Share-based compensation	29M	41M
Capital expenditure	2M	44M
Investing cash flow	−134M	−291M
Financing cash flow	241,000

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator